<p>Avidity Biosciences, Inc.（纳斯达克：RNA - 获取免费报告）的股价在周一的午盘交易中下跌了 4.6%。该公司的股价最低下跌至 44.40 美元，最后交易价为 44.78 美元。交易期间约有 43,088 股交易，较平均每日交易量 1,312,630 股下降了 97%。该股票先前收盘价为 46.95 美元。</p>
<p>获取 <strong>Avidity Biosciences</strong> 警报：</p>
<h2>分析师设定新的价格目标</h2>
<p>一些股票分析师最近发布了关于该股的报告。美国银行将 Avidity Biosciences 的股价目标从 40.00 美元提高到 45.00 美元，并在 6 月 13 日星期四的研究报告中给予该公司 “买入” 评级。Chardan Capital 将 Avidity Biosciences 的目标股价从 45.00 美元提高到 60.00 美元，并在周五的研究报告中给予该股 “买入” 评级。Evercore ISI 将 Avidity Biosciences 的目标股价从 45.00 美元提高到 54.00 美元，并在周一的研究报告中给予该公司 “表现优异” 评级。最后，Needham &amp; Company LLC 重申了对 Avidity Biosciences 股票的 “买入” 评级，并在 6 月 10 日星期一的报告中发布了 35.00 美元的价格目标。根据 MarketBeat，共有六位股票分析师对该股票给予买入评级，目前该公司的平均评级为 “买入”，共识价格目标为 50.67 美元。</p>
<p><strong>阅读我们关于 RNA 的最新研究报告</strong></p>
<h2>Avidity Biosciences 交易下跌 1.2%</h2>
<p>该公司的 50 天移动平均价格为 40.05 美元，两百天移动平均价格为 28.18 美元。该公司的市值为 44.3 亿美元，市盈率为-14.80，贝塔系数为 0.90。</p>
<p>Avidity Biosciences（纳斯达克：RNA - 获取免费报告）最近发布了其财报，日期为 5 月 15 日星期三。这家生物技术公司在该季度报告中每股亏损 0.79 美元，超过了分析师预期的每股亏损 0.81 美元。该公司在该季度的营收为 354 万美元，低于分析师预期的 709 万美元。Avidity Biosciences 的净资产回报率为-37.98%，净利润率为-2,103.78%。研究分析师平均预测，Avidity Biosciences, Inc.今年将发布-3.15 美元的每股收益。</p>
<h2>Avidity Biosciences 内部交易活动</h2>
<p>据相关消息，董事 Arthur A. Levin 于 5 月 20 日星期一出售了该公司股票的 5,000 股。这些股票的平均价格为 29.90 美元，总价值为 149,500.00 美元。交易完成后，该董事在公司中直接持有 14,830 股股票，价值约 443,417 美元。该交易已在提交给证券交易委员会的文件中披露，可通过此超链接查看。此外，首席执行官 Sarah Boyce 于 6 月 4 日星期二出售了 28,000 股 Avidity Biosciences 股票。这些股票的平均价格为 27.42 美元，总价值为 767,760.00 美元。交易完成后，首席执行官现在持有公司股票 112,117 股，价值 3,074,248.14 美元。该交易已在提交给证券交易委员会的文件中披露，可通过此超链接查看。此外，董事 Arthur A. Levin 于 5 月 20 日星期一出售了该公司股票的 5,000 股。这些股票的平均价格为 29.90 美元，总交易额为 149,500.00 美元。交易完成后，该董事现在直接持有该公司股票 14,830 股，价值约 443,417 美元。有关此交易的披露可在此处找到。在过去的九十天中，内部人士已出售了价值 17,491,990 美元的公司股票 482,478 股。公司股份的 3.68% 归内部人士所有。</p>
<h2>Avidity Biosciences 机构交易</h2>
<p>对冲基金和其他机构投资者最近买入和卖出了该股票。Nisa 投资顾问有限责任公司在第四季度增持了 Avidity Biosciences 的股份 15,900.0%。Nisa 投资顾问有限责任公司现在拥有该生物技术公司的 3,200 股股票，价值 29,000 美元，较上一季度增加了 3,180 股。Quadrant Capital Group 有限责任公司在第四季度增持了 Avidity Biosciences 的股份 456.9%。Quadrant Capital Group 有限责任公司现在拥有该生物技术公司的 3,308 股股票，价值 30,000 美元，较上一季度增加了 2,714 股。大和证券集团在第四季度增持了 Avidity Biosciences 的股份 43.3%。大和证券集团现在拥有该生物技术公司的 10,537 股股票，价值 95,000 美元，较上一季度增加了 3,182 股。nVerses Capital 有限责任公司在第二季度增持了 Avidity Biosciences 的股份 25.9%。nVerses Capital 有限责任公司现在拥有该生物技术公司的 3,400 股股票，价值 139,000 美元，较上一季度增加了 700 股。最后，Amalgamated Bank 在第二季度增持了 Avidity Biosciences 的股份 39.0%。Amalgamated Bank 现在拥有该生物技术公司的 3,497 股股票，价值 143,000 美元，较上一季度增加了 982 股。</p>
<h2>Avidity Biosciences 公司简介（获取免费报告）</h2>
<p>Avidity Biosciences, Inc 是一家生物制药公司，致力于 RNA 治疗的传递。它开发了抗体寡核苷酸结合物（AOC），旨在治疗以往无法用 RNA 治疗的疾病。该公司的主导产品候选药物 AOC 1001 用于治疗肌萎缩性脊髓肌肉营养不良 1 型，这是一种罕见的单基因肌肉疾病，目前处于 1/2 期临床试验阶段。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们喜欢的股票，胜过 Avidity Biosciences</li>
<li>什么是富时 100 指数？</li>
<li>如何投资白银：初学者指南</li>
<li>使用 MarketBeat 股息税计算器</li>
<li>Monday.com 的股票业绩将让任何投资者的一周变得更加光明</li>
<li>电动汽车股票及如何从中获利</li>
<li>高盛推荐后的三只必看股票</li>
</ul>
<p><em>这则即时新闻警报是由叙事科技和来自 MarketBeat 的金融数据生成的，旨在为读者提供最快速和最准确的报道。在发布之前，该故事已经经过 MarketBeat 编辑团队的审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
<p>→ 发现您的机会（查看详情）（来自 DTI）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MDg2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MDg2"/></p>
<h2>现在是否值得投资$1,000 到 Avidity Biosciences？</h2>
<p>在考虑投资 Avidity Biosciences 之前，您应该听听这个。</p>
<p>MarketBeat 追踪华尔街顶级和表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在购买的股票...而 Avidity Biosciences 并不在名单上。</p>
<p>虽然 Avidity Biosciences 目前在分析师中有一个 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

<p>Avidity Biosciences（纳斯达克股票代码：RNA）股价在周一盘中交易时下跌了 4.6%。该公司的股价下跌至 44.78 美元，交易量也有所减少。该股之前收盘价为 46.95 美元。几位股票分析师给予该股票 “买入” 评级，平均目标价为 50.67 美元。Avidity Biosciences 报告了季度超出预期的盈利结果。内部人士在过去三个月内大量出售了公司股票。对冲基金和其他机构投资者对该股表现出兴趣。该公司的市值为 44.3 亿美元</p>

<p>Avidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report)'s share price was down 4.6% during mid-day trading on Monday . The company traded as low as $44.40 and last traded at $44.78. Approximately 43,088 shares were traded during trading, a decline of 97% from the average daily volume of 1,312,630 shares. The stock had previously closed at $46.95.</p>
<div class="lb-trans"><p>Avidity Biosciences, Inc.（纳斯达克：RNA - 获取免费报告）的股价在周一的午盘交易中下跌了 4.6%。该公司的股价最低下跌至 44.40 美元，最后交易价为 44.78 美元。交易期间约有 43,088 股交易，较平均每日交易量 1,312,630 股下降了 97%。该股票先前收盘价为 46.95 美元。</p>
</div><p>Get <strong>Avidity Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Avidity Biosciences</strong> 警报：</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的价格目标</h2>
</div><p>Several equities analysts recently issued reports on the stock. Bank of America boosted their price target on shares of Avidity Biosciences from $40.00 to $45.00 and gave the company a &#34;buy&#34; rating in a research report on Thursday, June 13th. Chardan Capital increased their target price on Avidity Biosciences from $45.00 to $60.00 and gave the stock a &#34;buy&#34; rating in a research report on Friday. Evercore ISI raised their target price on Avidity Biosciences from $45.00 to $54.00 and gave the company an &#34;outperform&#34; rating in a research note on Monday. Finally, Needham &amp; Company LLC reiterated a &#34;buy&#34; rating and issued a $35.00 price objective on shares of Avidity Biosciences in a report on Monday, June 10th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of &#34;Buy&#34; and a consensus price target of $50.67.</p>
<div class="lb-trans"><p>一些股票分析师最近发布了关于该股的报告。美国银行将 Avidity Biosciences 的股价目标从 40.00 美元提高到 45.00 美元，并在 6 月 13 日星期四的研究报告中给予该公司 “买入” 评级。Chardan Capital 将 Avidity Biosciences 的目标股价从 45.00 美元提高到 60.00 美元，并在周五的研究报告中给予该股 “买入” 评级。Evercore ISI 将 Avidity Biosciences 的目标股价从 45.00 美元提高到 54.00 美元，并在周一的研究报告中给予该公司 “表现优异” 评级。最后，Needham &amp; Company LLC 重申了对 Avidity Biosciences 股票的 “买入” 评级，并在 6 月 10 日星期一的报告中发布了 35.00 美元的价格目标。根据 MarketBeat，共有六位股票分析师对该股票给予买入评级，目前该公司的平均评级为 “买入”，共识价格目标为 50.67 美元。</p>
</div><p><strong>Read Our Latest Research Report on RNA</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 RNA 的最新研究报告</strong></p>
</div><h2>Avidity Biosciences Trading Down 1.2 %</h2>
<div class="lb-trans"><h2>Avidity Biosciences 交易下跌 1.2%</h2>
</div><p>The firm has a 50 day moving average of $40.05 and a two-hundred day moving average of $28.18. The company has a market cap of $4.43 billion, a PE ratio of -14.80 and a beta of 0.90.</p>
<div class="lb-trans"><p>该公司的 50 天移动平均价格为 40.05 美元，两百天移动平均价格为 28.18 美元。该公司的市值为 44.3 亿美元，市盈率为-14.80，贝塔系数为 0.90。</p>
</div><p>Avidity Biosciences (NASDAQ:RNA - Get Free Report) last released its earnings results on Wednesday, May 15th. The biotechnology company reported ($0.79) EPS for the quarter, topping analysts' consensus estimates of ($0.81) by $0.02. The firm had revenue of $3.54 million for the quarter, compared to analysts' expectations of $7.09 million. Avidity Biosciences had a negative return on equity of 37.98% and a negative net margin of 2,103.78%. On average, research analysts forecast that Avidity Biosciences, Inc. will post -3.15 EPS for the current year.</p>
<div class="lb-trans"><p>Avidity Biosciences（纳斯达克：RNA - 获取免费报告）最近发布了其财报，日期为 5 月 15 日星期三。这家生物技术公司在该季度报告中每股亏损 0.79 美元，超过了分析师预期的每股亏损 0.81 美元。该公司在该季度的营收为 354 万美元，低于分析师预期的 709 万美元。Avidity Biosciences 的净资产回报率为-37.98%，净利润率为-2,103.78%。研究分析师平均预测，Avidity Biosciences, Inc.今年将发布-3.15 美元的每股收益。</p>
</div><h2>Insider Activity at Avidity Biosciences</h2>
<div class="lb-trans"><h2>Avidity Biosciences 内部交易活动</h2>
</div><p>In related news, Director Arthur A. Levin sold 5,000 shares of the business's stock in a transaction that occurred on Monday, May 20th. The shares were sold at an average price of $29.90, for a total value of $149,500.00. Following the completion of the transaction, the director now directly owns 14,830 shares in the company, valued at approximately $443,417. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, CEO Sarah Boyce sold 28,000 shares of Avidity Biosciences stock in a transaction on Tuesday, June 4th. The stock was sold at an average price of $27.42, for a total value of $767,760.00. Following the completion of the sale, the chief executive officer now owns 112,117 shares of the company's stock, valued at $3,074,248.14. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Also, Director Arthur A. Levin sold 5,000 shares of the company's stock in a transaction dated Monday, May 20th. The shares were sold at an average price of $29.90, for a total transaction of $149,500.00. Following the sale, the director now directly owns 14,830 shares of the company's stock, valued at approximately $443,417. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 482,478 shares of company stock valued at $17,491,990. 3.68% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>据相关消息，董事 Arthur A. Levin 于 5 月 20 日星期一出售了该公司股票的 5,000 股。这些股票的平均价格为 29.90 美元，总价值为 149,500.00 美元。交易完成后，该董事在公司中直接持有 14,830 股股票，价值约 443,417 美元。该交易已在提交给证券交易委员会的文件中披露，可通过此超链接查看。此外，首席执行官 Sarah Boyce 于 6 月 4 日星期二出售了 28,000 股 Avidity Biosciences 股票。这些股票的平均价格为 27.42 美元，总价值为 767,760.00 美元。交易完成后，首席执行官现在持有公司股票 112,117 股，价值 3,074,248.14 美元。该交易已在提交给证券交易委员会的文件中披露，可通过此超链接查看。此外，董事 Arthur A. Levin 于 5 月 20 日星期一出售了该公司股票的 5,000 股。这些股票的平均价格为 29.90 美元，总交易额为 149,500.00 美元。交易完成后，该董事现在直接持有该公司股票 14,830 股，价值约 443,417 美元。有关此交易的披露可在此处找到。在过去的九十天中，内部人士已出售了价值 17,491,990 美元的公司股票 482,478 股。公司股份的 3.68% 归内部人士所有。</p>
</div><h2>Institutional Trading of Avidity Biosciences</h2>
<div class="lb-trans"><h2>Avidity Biosciences 机构交易</h2>
</div><p>Hedge funds and other institutional investors have recently bought and sold shares of the stock. Nisa Investment Advisors LLC lifted its stake in shares of Avidity Biosciences by 15,900.0% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,200 shares of the biotechnology company's stock valued at $29,000 after buying an additional 3,180 shares in the last quarter. Quadrant Capital Group LLC grew its position in shares of Avidity Biosciences by 456.9% during the fourth quarter. Quadrant Capital Group LLC now owns 3,308 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 2,714 shares in the last quarter. Daiwa Securities Group Inc. increased its holdings in shares of Avidity Biosciences by 43.3% in the fourth quarter. Daiwa Securities Group Inc. now owns 10,537 shares of the biotechnology company's stock worth $95,000 after purchasing an additional 3,182 shares during the last quarter. nVerses Capital LLC lifted its position in shares of Avidity Biosciences by 25.9% in the second quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company's stock worth $139,000 after buying an additional 700 shares in the last quarter. Finally, Amalgamated Bank boosted its stake in Avidity Biosciences by 39.0% during the second quarter. Amalgamated Bank now owns 3,497 shares of the biotechnology company's stock valued at $143,000 after buying an additional 982 shares during the last quarter.</p>
<div class="lb-trans"><p>对冲基金和其他机构投资者最近买入和卖出了该股票。Nisa 投资顾问有限责任公司在第四季度增持了 Avidity Biosciences 的股份 15,900.0%。Nisa 投资顾问有限责任公司现在拥有该生物技术公司的 3,200 股股票，价值 29,000 美元，较上一季度增加了 3,180 股。Quadrant Capital Group 有限责任公司在第四季度增持了 Avidity Biosciences 的股份 456.9%。Quadrant Capital Group 有限责任公司现在拥有该生物技术公司的 3,308 股股票，价值 30,000 美元，较上一季度增加了 2,714 股。大和证券集团在第四季度增持了 Avidity Biosciences 的股份 43.3%。大和证券集团现在拥有该生物技术公司的 10,537 股股票，价值 95,000 美元，较上一季度增加了 3,182 股。nVerses Capital 有限责任公司在第二季度增持了 Avidity Biosciences 的股份 25.9%。nVerses Capital 有限责任公司现在拥有该生物技术公司的 3,400 股股票，价值 139,000 美元，较上一季度增加了 700 股。最后，Amalgamated Bank 在第二季度增持了 Avidity Biosciences 的股份 39.0%。Amalgamated Bank 现在拥有该生物技术公司的 3,497 股股票，价值 143,000 美元，较上一季度增加了 982 股。</p>
</div><h2>Avidity Biosciences Company Profile (Get Free Report)</h2>
<div class="lb-trans"><h2>Avidity Biosciences 公司简介（获取免费报告）</h2>
</div><p>Avidity Biosciences, Inc, a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial.</p>
<div class="lb-trans"><p>Avidity Biosciences, Inc 是一家生物制药公司，致力于 RNA 治疗的传递。它开发了抗体寡核苷酸结合物（AOC），旨在治疗以往无法用 RNA 治疗的疾病。该公司的主导产品候选药物 AOC 1001 用于治疗肌萎缩性脊髓肌肉营养不良 1 型，这是一种罕见的单基因肌肉疾病，目前处于 1/2 期临床试验阶段。</p>
</div><h2>Featured Articles</h2>
<ul>
<li>Five stocks we like better than Avidity Biosciences</li>
<li>What is the FTSE 100 index?</li>
<li>How to Invest in Silver: A Beginner's Guide</li>
<li>Using the MarketBeat Dividend Tax Calculator</li>
<li>Monday.com's Stock Results Will Brighten Any Investor's Week</li>
<li>EV Stocks and How to Profit from Them</li>
<li>3 Must-Watch Stocks After a Bullish Goldman Sachs Recommendation</li>
</ul>
<div class="lb-trans"><h2>精选文章</h2>
<ul>
<li>五只我们喜欢的股票，胜过 Avidity Biosciences</li>
<li>什么是富时 100 指数？</li>
<li>如何投资白银：初学者指南</li>
<li>使用 MarketBeat 股息税计算器</li>
<li>Monday.com 的股票业绩将让任何投资者的一周变得更加光明</li>
<li>电动汽车股票及如何从中获利</li>
<li>高盛推荐后的三只必看股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由叙事科技和来自 MarketBeat 的金融数据生成的，旨在为读者提供最快速和最准确的报道。在发布之前，该故事已经经过 MarketBeat 编辑团队的审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><p>→ Unlock Your Opportunity (See inside) (From DTI)(Ad)</p>
<div class="lb-trans"><p>→ 发现您的机会（查看详情）（来自 DTI）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MDg2" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9086&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Avidity Biosciences right now?</h2>
<div class="lb-trans"><h2>现在是否值得投资$1,000 到 Avidity Biosciences？</h2>
</div><p>Before you consider Avidity Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 Avidity Biosciences 之前，您应该听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avidity Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追踪华尔街顶级和表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在购买的股票...而 Avidity Biosciences 并不在名单上。</p>
</div><p>While Avidity Biosciences currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Avidity Biosciences 目前在分析师中有一个 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Avidity Biosciences（纳斯达克代码：RNA）股价下跌 4.6%